title: Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.
abstract: OBJECTIVE
  Evaluating safety and tolerability of the selective A2A receptor agonist, regadenoson, in patients referred for single photon emission computed tomography myocardial perfusion imaging (MPI).
  
  
  METHODS
  Observational study of patients referred for MPI stress testing using a 400 μg regadenoson (Rapiscan(®)) bolus. Hemodynamic variables and severity of adverse events (AE) were recorded before, during, and after administration.
  
  
  RESULTS
  A total of 232 patients were included. One or more AE were reported in 90% of patients; the AEs were graded mostly mild to moderate in severity, resolved spontaneously, and were mainly dyspnea, headache, and chest pain. No advanced heart block or bronchospasm were seen. Transient ST-segment changes developed in 10 patients. The maximum increase in heart rate was 19 ± 11 beats/minute. The mean systolic blood pressure decreased from 144 to 139 mmHg (p < 0.0001). Medical intervention was required in three patients: one case with severe hypotension and two cases with chest pain that was relieved with sublingual nitroglycerin. One patient died the day after stress MPI for reasons considered unrelated to regadenoson.
  
  
  CONCLUSIONS
  Regadenoson for MPI is easy to use with a high frequency of AEs, which are generally mild in severity, transient, and resolve spontaneously.
authors.affiliation: a The Department of Cardiology , Aalborg University Hospital , Aalborg , Denmark ;
authors.forename: Marianne
authors.initials: M
authors.lastname: Pape
authors.affiliation: b The Department of Nuclear Medicine , Aalborg University Hospital , Aalborg , Denmark ;|c The Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.
authors.forename: Helle D
authors.initials: HD
authors.lastname: Zacho
authors.affiliation: a The Department of Cardiology , Aalborg University Hospital , Aalborg , Denmark ;
authors.forename: Jens
authors.initials: J
authors.lastname: Aarøe
authors.affiliation: a The Department of Cardiology , Aalborg University Hospital , Aalborg , Denmark ;|c The Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.
authors.forename: Svend
authors.initials: S
authors.lastname: Eggert Jensen
authors.affiliation: b The Department of Nuclear Medicine , Aalborg University Hospital , Aalborg , Denmark ;|c The Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.
authors.forename: Lars J
authors.initials: LJ
authors.lastname: Petersen
mesh_terms: D058908:Adenosine A2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects; D000368:Aged; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000453:epidemiology; D003718:Denmark / Q000453:epidemiology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D004562:Electrocardiography / Q000379:methods; D005080:Exercise Test / Q000379:methods; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D011687:Purines / Q000008:administration & dosage / Q000009:adverse effects; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: D058908:Adenosine A2 Receptor Agonists; D011687:Purines; D011720:Pyrazoles; C430916:regadenoson
keywords: Adverse event; myocardial perfusion imaging; regadenoson; safety; stress testing